Successful clinical response to irinotecan in desmoplastic round blue cell tumor

Rosoff, Philip M.; Bayliff, Sherry

doi:10.1002/(sici)1096-911x(199911)33:5<500::aid-mpo12>3.0.co;2-x

Cited by 36 publications

(30 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preclinical studies using xenografts of pediatric solid tumors, including NB, favor 5-or 10-day schedules, and the few published clinical reports support that timing. Thus, in pediatric phase I studies, (12)(13)(14) and in small pilot studies (15,18), irinotecan administered at 50 -200 mg/m 2 /day ϫ3 days (14), at 30 -65 mg/m 2 /day ϫ5 days, (12,18), or at 20 -29 mg/m 2 /day ϫ10 days (13,15) produced favorable results in patients with NB or other solid tumors. In contrast, the sole phase II trial of irinotecan for NB reported to date used a single dose of 600 mg/m 2 every 3 weeks but, despite the higher dosage than in the 3-, 5-, or 10-day regimens, yielded "no clinically useful activity" (16).…”

Section: Discussionmentioning

confidence: 99%

Camptothecin Analogs (Irinotecan or Topotecan) plus High-Dose Cyclophosphamide as Preparative Regimens for Antibody-Based Immunotherapy in Resistant Neuroblastoma

Kushner

Krämer

Modak

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Camptothecin Analogs (Irinotecan or Topotecan) plus High-Dose Cyclophosphamide as Preparative Regimens for Antibody-Based Immunotherapy in Resistant Neuroblastoma

Kushner

Krämer

Modak

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…[8] Successful clinical response was reported by Philip M Rosoft et al with Irinotecan and hence suggests trials with Irinotecan alone or in combination. [17] Current treatment prolongs life and rarely achieves cure. Neoadjuvant chemotherapy, greater than 90% tumor debulking, and radiotherapy have been shown to prolong survival.…”

Section: Discussionmentioning

confidence: 99%

Desmoplastic small round cell tumor: Extra abdominal and abdominal presentations and the results of treatment

et al. 2005

View full text Add to dashboard Cite

BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is a rare malignant neoplasm of adolescent males.Current multimodality treatment prolongs life and rarely achieves cure. AIM: To review the presenting features, histopathology and outcome of 18 patients with DSRCT treated at a single institution. SETTING AND DESIGN:This is a retrospective observational study of patients with DSRCT who presented at the Tata Memorial Hospital between January 1994 to January 2005. MATERIALS AND METHODS: Eighteen patients of DSRCT seen during this period were evaluated for their clinical presentation, response to chemotherapy and other multimodality treatment and overall survival. The cohort of 18 patients included 11 males (61%) and 7 females (39%) with a mean age of 16 years (Range 1½ -30 years). Majority (83%) presented with abdomino-pelvic disease. The others, involving chest wall and extremities. There were 6 patients (33%) with metastatic disease at presentation. RESULTS: The treatment primarily included a multimodality approach using a combination of multiagent chemotherapy with adjuvant surgery and radiotherapy as applicable. A response rate of 39% (CR-1, PR-6), with chemotherapy was observed. The overall response rate after multimodality treatment was 39% (CR-5, PR-2). The overall survival was poor except in patients who had complete excision of the tumor. CONCLUSION: Abdomino-pelvic site was the commonest presentation, the disease can occur at other non-serosal surfaces also. Despite aggressive treatment the outcome was poor. However, complete surgical excision seems to provide a better survival.

show abstract

“…The PR was achieved in leiomyosarcoma, rhabdomyosarcoma, neuroblastoma [69], undifferentiated sarcoma, and Wilms' tumor ( Table 2). As a single, independent experience, Rosoff and Bayliff [70] administered irinotecan 50 mg/m 2 /day for 5 days every 3−4 weeks in 2 patients with desmoplastic round blue cell tumors and saw significant responses. As far as the treatment of childhood solid tumors is concerned, at present irinotecan appears to be promising in the treatment of childhood solid tumors such as rhabdomyosarcoma, neuroblastoma, and desmoplastic round blue cell tumor [55,58,66,[68][69][70].…”

Section: Phase II Studiesmentioning

confidence: 99%

Topotecan and Irinotecan in the Treatment of Pediatric Solid Tumors

Tsuchida¹,

Shitara

2005

CPR

View full text Add to dashboard Cite

There have been significant advances in the treatment of neuroblastoma and rhabdomyosarcoma, but the clinical results are still poor, especially after tumor relapse. In addition to this, rhabdomyosarcoma does worse if localized tumors occur in unfavorable sites. Therefore, new chemotherapeutic agents have been sought, and the effects of 9-dimethylaminomethyl-10-hydroxycampthothecin (topotecan) and 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonylcamptothecin hydrochloride (irinotecan) were studied preclinically and clinically during the past decade not only in adults but also in children. Irinotecan and topotecan inhibit DNA topoisomerase I, which is an essential nuclear enzyme that relaxes torsionally strained duplex DNA, enabling replication and transcription. These agents were reported to be effective against various human malignancies in adults. Among these camptothecin derivatives, topotecan and irinotecan are the most widely used clinically, and at present irinotecan appears to be more promising in the treatment of childhood solid tumors such as rhabdomyosarcoma and neuroblastoma. The recommended dose and administration schedule differ among clinical trials.. For example, 1-day, 3-day, and 10-day regimens have been used. In the present article, the clinical effectiveness of topotecan and irinotecan with different administration schedules are reviewed in the US, French and Japanese literature, and the authors propose which agent and which administration schedule of these agents are the most effective in the treatment of pediatric solid tumors. DEVELOPMENT OF TOPOTECAN AND IRINOTECANSignificant advances in survival rates have been achieved in the treatment of several pediatric solid tumors such as advanced neuroblastoma [1,2] and rhabdomyosarcoma [3,4], but the clinical results are still unsatisfactory, especially in patients with disseminated disease. Therefore, numerous new agents such as paclitaxel, fotemustine, busulfan, mitomycin C, ifosfamide, and bleomycin have been investigated for their efficacy in preclinical studies [5][6][7], and only a few were found to be sufficiently promising to be incorporated in clinical trials. The topoisomerase I inhibitors topotecan and irinotecan are examples of such promising agents.In the Yangtze River basin of China, elderly Chinese are aware that leaves of the tree Camptotheca acuminata are effective against human gastric cancer. The antitumor activity of 20(S)-camptothecin, a plant alkaloid isolated from C. acuminata, was first studied more than 20 years ago [8].Although 20(S)-camptothecin is insoluble in aqueous vehicles, extensive investigation has identified more soluble and active camptothecin analogs. The water-soluble analog, 9-di me t hy la m in ome th yl-10 -hy dr oxy -c a mp tot he c in ( to po tecan) demonstrate sbroad-spectrum activity against rodent tumor models [9] and significant therapeutic activity against some human colon adenocarcinoma xenografts [10].Another water-soluble derivative of camptothecin, 7-e t hy l -1 0-( 4-[ 1 -pi p e r id i n o ]-1...

show abstract

Successful clinical response to irinotecan in desmoplastic round blue cell tumor

Cited by 36 publications

References 21 publications

Camptothecin Analogs (Irinotecan or Topotecan) plus High-Dose Cyclophosphamide as Preparative Regimens for Antibody-Based Immunotherapy in Resistant Neuroblastoma

Camptothecin Analogs (Irinotecan or Topotecan) plus High-Dose Cyclophosphamide as Preparative Regimens for Antibody-Based Immunotherapy in Resistant Neuroblastoma

Desmoplastic small round cell tumor: Extra abdominal and abdominal presentations and the results of treatment

Topotecan and Irinotecan in the Treatment of Pediatric Solid Tumors

Contact Info

Product

Resources

About